 |
| |
| |
 |
| Trubion Pharmaceuticals, Inc. (TRBN) |
OBP IV |
Seattle, WA
www.trubion.com
Trubion is focused on the discovery and development of single chain antibodies to treat autoimmune and cancer indications.
|
|
 |
| |
 |
| Gene Logic Inc. (GLGC) |
OBP I, II |
Gaithersburg, MD
www.genelogic.com
Gene Logic is the leading provider of bioinformation products based upon the use of microarray technology for gene expression profiling of biological systems.
|
|
|
| |
 |
| Human Genome Sciences, Inc. (HGSI) |
OBP I |
Rockville, MD
www.hgsi.com
Human Genome Sciences, Inc. identifies and commercializes genes for human therapeutic development.
|
|
|
| |
 |
| Exelixis, Inc. (EXEL) |
OBP I, II |
South San Francisco, CA
www.exelixis.com
Exelixis is a drug discovery company with expertise in comparative genomics and model
system genetics used to identify key members of critical disease pathways in diseases such as cancer.
|
|
|
| |
 |
| Genset S.A. (GENXY) |
OBP I |
Paris, France
Genset is the first significant French genomics company.
|
|
|
| |
 |
| ACADIA Pharmaceuticals Inc. (ACAD) |
OBP IV |
San Diego, CA
www.acadia-pharm.com
Acadia is a small molecule drug discovery and development company to identify novel chemistries focused on diseases such as Parkinson's, psychosis, chronic pain and glaucoma.
|
|
|
| |
 |
| Asterand plc (LSE: ATD) |
OBP III |
(Merged with Pharmagene plc to form new company, Asterand plc)
Royston, Herts, U.K. and Detroit, MI
www.asterand.com
Asterand plc specializes in providing essential tissue samples and information for use in cutting edge genomics research.
|
|
|
| |
 |
| Avalon Pharmaceuticals, Inc. (AVRX) |
OBP III |
Germantown, MD
www.avalonrx.com
Avalon develops cancer therapeutics using genomics and gene signatures.
|
|
|
| |
 |
| Cardiome Pharma Corp (CRME) |
OBP IV |
Vancouver, British Columbia
www.cardiome.com
Cardiome is a product-focused cardiovascular drug development company focused on atrial arrhythmia and congestive heart failure.
|
|
|
| |
 |
| Critical Therapeutics, Inc. (CRTX) |
OBP IV |
Cambridge, MA
www.criticaltherapeutics.com
Critical Therapeutics is focused on critical care medicine, with a mission to discover, develop and commercialize novel therapies for the treatment of acute trauma, cardiopulmonary disease and infectious and inflammatory illness.
|
|
|
| |
 |
| Cyberkinetics Neurotechnology Systems, Inc. (CYKN) |
OBP IV |
Foxboro, MA
www.cyberkineticsinc.com
Cyberkinetics is a leading neurotechnology company, building direct brain-computer interfaces to treat individuals affected by paralysis or neurological disorders. Cyberkinetics’ intellectual property features key technologies licensed from Brown University, the Massachusetts Institute of Technology, Emory University, and the University of Utah. Cyberkinetics is headquartered in Foxborough, Massachusetts, and maintains an engineering group in Salt Lake City, Utah.
|
|
|
| |
 |
| ExonHit Therapeutics, S.A. (ALEHT) |
OBP II |
Paris, France
www.exonhit.com
ExonHit Therapeutics is a drug discovery and development company using analysis of RNA splicing events as the basis for target identification and lead selection.
|
|
|
| |
 |
| Genetic Therapy, Inc. |
OBP I |
Gaithersburg, MD
Genetic Therapy was a company dedicated to bringing to market gene therapy products
for the treatment of life-threatening genetic and acquired diseases.
It was sold to Novartis(NVS) in 1995.
|
|
|
| |
 |
| Geron Corporation (GERN) |
OBP I |
Menlo Park, CA
www.geron.com
Geron develops and commercializes therapeutic and diagnostic products for oncology and regenerative medicine.
|
|
|
| |
 |
| Illumina, Inc. (ILMN) |
OBP III, IV |
San Diego, CA
www.illumina.com
Illumina develops tools for large-scale analysis of genetic variations and gene function.
|
|
|
| |
 |
| Inkine Pharmaceutical Company, Inc. (INKP) |
OBP II |
Blue Bell, PA
www.inkine.com
InKine Pharmaceutical Company, Inc. is a publicly-traded biopharmaceutical
company that focuses on the diagnosis and treatment of cancer and autoimmune disease.
Its products include Visicol™ and Colirest™.
|
|
|
| |
 |
| Inverness Medical Innovations, Inc. (IMA) |
OBP IV |
Waltham, MA
www.invernessmedical.com
Inverness Medical Innovations, Inc. is developing innovative consumer OTC products focused on the
self-management of diabetes, pregnancy and ovulation, as well as manufacturing and marketing a line
of nutritional supplements.
|
|
|
| |
 |
| Memory Pharmaceuticals Corp. (MEMY) |
OBP II; IV |
Montvale, NJ
www.memorypharma.com
Memory Pharmaceuticals develops drugs for the treatment of cognitive disorders associated with disease and aging.
|
|
|
| |
 |
| MicroMed Cardiovascular, Inc. (MMCV) |
OBP II |
Houston, TX
www.micromedcv.com
MicroMed develops and commercializes a miniature, implantable left ventricular assist device (LVAD), originally developed at NASA and further refined for clinical use by the famed heart surgeon, Dr. Michael DeBakey, for use as a bridge-to-transplant for congestive heart patients awaiting a heart transplantation.
|
|
|
| |
 |
| Nuvelo, Inc. (NUVO) |
OBP II |
(Formerly Variagenics, Inc.; Acquired by HYSEQ Pharmaceuticals, Inc. to form new company, Nuvelo, Inc.)
Sunnyvale, CA
www.nuvelo.com
Nuvelo exists to optimize therapeutic outcomes for patients and their prescribing physicians by applying
pharmacogenomics, or the understanding of the influence of genetic variation on drug response, to the
development of drugs and related diagnostics.
|
|
|
| |
 |
| Orchid BioSciences, Inc. (ORCH) |
OBP II |
Princeton, NJ
www.orchid.com
Orchid BioSciences is now a leading provider of products, services and technologies for
single nucleotide polymorphism (SNP) scoring and genetic diversity analyses.
|
|
|
| |
 |
| QuadraMed Corporation (QMDC) |
OBP I |
San Rafael, CA
www.quadramed.com
QuadraMed develops acute care information management solutions for health care professionals.
|
|
|
| |
 |
| Salix Pharmaceuticals, Ltd. (SLXP) |
OBP III |
Raleigh, NC
www.salixltd.com
Salix Pharmaceuticals, Ltd. identifies and acquires late-stage proprietary pharmaceutical
products having an existing base of safety and efficacy data in humans for the treatment
of gastrointestinal disease and applies the company’s regulatory, product development,
and sales and marketing expertise to commercialize these products.
|
|
|
| |
 |
| Santhera Pharmaceuticals AG (SANN) |
OBP III |
(Formerly Graffinity Pharmaceuticals AG; merged with MyoContract AG to form new company, Santhera Pharmaceuticals AG)
Liestal (Basel), Switzerland and Heidelberg, Germany
www.santhera.com
Santhera focuses on the discovery, development and commercialization of small molecule drugs in the areas of neuromuscular and metabolic diseases.
|
|
|
| |
 |
| Sosei Co., Ltd. (Nikkei: 4565) |
OBP I |
Tokyo, Japan
www.sosei.com
Sosei is focused on (i) helping to expedite the commercialization of Japanese university-based technologies, (ii) effecting change in the methods of technology transfer between Japan and the U.S., and (iii) providing a reliable platform in Japan for small, innovative U.S. businesses seeking Japanese corporate partners.
|
|
|
| |
 |
| Targacept, Inc. (TRGT) |
OBP IV |
Winston-Salem, NC
www.targacept.com
Targacept, Inc. was spun out of RJ Reynolds and focuses on novel therapeutics in neurological, psychiatric and GI arenas. The company has products that focus on dementia and ulcerative colitis.
|
|
|
| |
 |
| VIVUS, Inc. (VVUS) |
OBP I |
Mountain View, CA
www.vivus.com
Vivus, Inc. is a pharmaceutical company engaged in developing, acquiring and marketing
innovative products to improve quality of life disorders in men and women,
with a focus on sexual dysfunction.
|
|
|
| |